Equities Analysts Offer Predictions for argenx Q3 Earnings

argenx SE (NASDAQ:ARGX) – Equities research analysts at HC Wainwright increased their Q3 2025 earnings estimates for argenx in a report released on Friday, February 28th. HC Wainwright analyst D. Tsao now expects that the company will post earnings per share of $1.68 for the quarter, up from their previous forecast of $1.65. HC Wainwright has a “Buy” rating and a $720.00 price target on the stock. The consensus estimate for argenx’s current full-year earnings is $3.13 per share. HC Wainwright also issued estimates for argenx’s FY2025 earnings at $6.50 EPS.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.98 by $0.60. The business had revenue of $761.22 million for the quarter, compared to the consensus estimate of $678.52 million. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%.

ARGX has been the topic of a number of other research reports. Deutsche Bank Aktiengesellschaft downgraded shares of argenx from a “hold” rating to a “sell” rating in a research report on Friday, January 17th. Oppenheimer raised their target price on shares of argenx from $675.00 to $704.00 and gave the company an “outperform” rating in a research note on Friday, February 28th. Robert W. Baird upped their price target on argenx from $650.00 to $680.00 and gave the stock a “neutral” rating in a research report on Tuesday. Scotiabank raised argenx from a “sector perform” rating to a “sector outperform” rating and raised their price objective for the stock from $439.00 to $715.00 in a research report on Tuesday, November 5th. Finally, Truist Financial restated a “buy” rating and set a $700.00 target price (up from $660.00) on shares of argenx in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $662.83.

argenx Price Performance

ARGX opened at $621.25 on Monday. The firm has a market capitalization of $37.75 billion, a PE ratio of -705.97 and a beta of 0.58. The business’s 50-day moving average is $642.51 and its two-hundred day moving average is $591.91. argenx has a 1 year low of $349.86 and a 1 year high of $678.21.

Institutional Trading of argenx

Several large investors have recently made changes to their positions in the business. GeoWealth Management LLC raised its holdings in shares of argenx by 56.3% during the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company’s stock worth $31,000 after purchasing an additional 18 shares during the last quarter. Steward Partners Investment Advisory LLC grew its position in argenx by 5.6% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 380 shares of the company’s stock worth $234,000 after purchasing an additional 20 shares during the period. SG Americas Securities LLC raised its stake in shares of argenx by 6.2% during the 4th quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after buying an additional 21 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of argenx by 38.2% in the 4th quarter. Farther Finance Advisors LLC now owns 76 shares of the company’s stock valued at $47,000 after buying an additional 21 shares during the period. Finally, Dynasty Wealth Management LLC lifted its holdings in shares of argenx by 3.4% in the 4th quarter. Dynasty Wealth Management LLC now owns 677 shares of the company’s stock valued at $416,000 after buying an additional 22 shares during the period. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.